Trial Profile
Non-interventional Study Describing Patients´ Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamine K Antagonist for Stroke Prevention in Non-Valvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Stroke
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms RE-SONANCE
- Sponsors Boehringer Ingelheim
- 22 Jun 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017.